Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancer

Sponsor:

Lung Cancer Mutation Consortium

Sponsor Study ID:

LCMC4

CTO #:

103745

NCT Number:

NCT04712877

Phase:

N/A

Protocol Type:

Screening

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

The primary objective of this study is to determine the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. The screening approach will be considered feasible if, utilizing tumor or plasma assays, 35% of non-squamous non-small cell lung cancers are identified as having a actionable genomic alteration including ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, KRAS G12C, or ROS1 rearrangements

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)